MedUni Vienna: Safe and effective - wound healing preparation reaches clinical phase II

Study investigates efficacy in diabetic foot ulcers - Data Safety Monitoring Board recommends continuation

APO-2 (Aposec) is a secretome-based trial preparation derived from stressed peripheral blood mononuclear cells. APO-2 was shown to be safe and effective in a multinational Phase I study in patients with diabetic foot ulcers (non-healing foot ulcers). The Data Safety Monitoring Board has therefore recommended continuation into a Phase II clinical trial. This represents a major success for the wound healing preparation developed at MedUni Vienna.

APO-2 contains the secretome (released substances) of stressed blood mononuclear cells, a current waste product from transfusion units. This new technology harnesses the power of these blood cells, immunology and biotechnology to overcome tissue damage and wound healing disorders. It is produced by the Blood Donor Service of the Upper Austria Red Cross in compliance with Good Manufacturing Practice.

Secretome-based wound healing treatment for diabetic foot ulcers

The MARSYAS II clinical trial is the first study to test a secretome-based wound healing treatment in patients with diabetic foot ulcers. APO-2 is applied three times a week for four consecutive weeks. In the main phase (Phase II) of the clinical trial, three different doses of APO-2 are being evaluated. Clinical-stage company Aposcience AG, a MedUni Vienna spin-off, is conducting the study at an international level together with partners FGK Clinical Research GmbH (Munich, Germany) and ABF Pharmaceutical Services GmbH (Vienna).

"Our Phase I study has confirmed that this novel agent is safe for patients with diabetic foot ulcers. Only the data from the Phase II trial will show whether the massive investment in preclinical research and product science has paid off," says Hendrik Jan Ankersmit from the Department of Thoracic Surgery at MedUni Vienna and Vienna General Hospital. The Data Safety Monitoring Board (DSMB) unanimously recommended proceeding with the main phase of the MARSYAS II trial.

The burden of diabetes

According to the International Diabetes Federation, 8.9% of adults aged between 20 to 79 in Europe suffered from diabetes in 2019, equating tor 59.3 million people. Another 296,500 children and adolescents under the age of 20 are living with type 1 diabetes. Diabetes is among the top ten causes of non-communicable disease-related deaths. Significant complications of diabetes mellitus are impaired wound healing and the development of foot ulcers. Foot ulcers that do not heal can lead to amputation and premature death.

Public-private partnership with Aposcience AG

Aposcience AG is a privately run Austrian clinical-stage company founded by Hendrik Jan Ankersmit in 2008. It was founded as a spin-off of the Department of Surgery of the Medical University of Vienna. The close collaboration between Aposcience and the Medical University of Vienna was funded by the Christian Doppler Society, the Austrian Research Promotion Agency FFG and Vienna Business Agency and is a good example of a public-private partnership.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.